A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Inclusion Criteria:

• Adolescent participants (defined as greater than or equal to [>=] 12 and less than [<] 18 years of age) are only eligible for the relapsed/refractory (R/R) cohort (ArmA, cohort A4)

• Diagnosis of AML according to World Health Organization (WHO) criteria: a) De novoor secondary AML; b) relapsed/refractory (Arm A only); c) harboring KMT2A, NPM1,NUP98, or NUP214 alterations; d) Participants may receive emergency leukapheresisand/or cytarabine as cytoreductive therapy according to local practice guidelines

• Pretreatment clinical laboratory values meeting the following criteria -listedbelow: White blood cell (WBC) count: less than or equal to (<=) 25*10^9 per liter (/L), adequate liver and renal function

• Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2.Adolescent participants only: Performance status >70 by Lansky scale (forparticipants <16 years of age) or >70 Karnofsky scale (for participants >16 years ofage)

• A female of childbearing potential must have a negative highly sensitive serumbeta-human chorionic gonadotropin at screening and within 48 hours prior to thefirst dose of study treatment

• Must sign an informed consent form (ICF) indicating participant (or their legallyauthorized representative) understands the purpose of the study and proceduresrequired for the study and is willing to participate in the study

• Willing and able to adhere to the prohibitions and restrictions specified in thisprotocol

Exclusion Criteria:

• Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia orjuvenile myelomonocytic leukemia according to WHO 2016 criteria

• Leukemic involvement of the central nervous system

• Recipient of solid organ transplant

• Cardiovascular disease that is uncontrolled, increases risk for Torsades de Pointesor that was diagnosed within 6 months prior to the first dose of study treatmentincluding, but not limited to: (a) Myocardial infarction; (b) Severe or unstableangina; (c) Clinically significant cardiac arrhythmias, including bradycardia (<50beats per minute); (d) Uncontrolled (persistent) hypertension: (example, bloodpressure greater than [>] 140/90 millimeters of mercury [mm Hg]; (e) Acuteneurologic events such as stroke or transient ischemic attack, intracranial orsubarachnoid hemorrhage, intracranial trauma; (f) Venous thromboembolic events (example, pulmonary embolism) within 1 month prior to the first dose of studytreatment ;(g) Congestive heart failure (NYHA class III to IV); (h) Pericarditis orclinically significant pericardial effusion; (i) Myocarditis; (j) Endocarditis (k)Clinically significant hypokalemia, hypomagnesemia, hypocalcemia (corrected forhypoalbuminemia)

• Any toxicity (except for alopecia, stable peripheral neuropathy, thrombocytopenia,neutropenia, anemia) from previous anticancer therapy that has not resolved tobaseline or to grade 1 or less

• Pulmonary compromise that requires the need for supplemental oxygen use to maintainadequate oxygenation

• Participants with diagnosis of Fanconi anemia, Kostmann syndrome, Shwachman diamondsyndrome, or any other known bone marrow failure syndrome